Skip to main content
. 2020 Apr 24;9(9):e014347. doi: 10.1161/JAHA.119.014347

Figure 1. Use of lipid‐lowering medication within 31 to 365 days before initiation of a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i).

Figure 1

This figure depicts which lipid‐lowering medications were used in the 31 to 365 days before initiation of a PCSK9i, including the statin intensity. High intensity statins included atorvastatin, ≥40 mg/d, rosuvastatin, ≥20 mg/d, and simvastatin, 80 mg/d. Moderate‐intensity statins included pitavastatin, ≥2 mg, rosuvastatin, 10 mg, atorvastatin, 10 or 20 mg, pravastatin, ≥40 mg, fluvastatin, >80 mg, simvastatin, 20 to 40 mg, and lovastatin, ≥40 mg. Low‐intensity statins included pitavastatin, 1 mg, rosuvastatin, 5 mg, pravastatin, ≤40 mg, fluvastatin, ≤80 mg, simvastatin, ≤20 mg, and lovastatin, ≤40 mg. LLTT indicates lipid‐lowering therapy.